Clinical trial NCT02757872
Conditions: Hypertension Kidney Diseases
Keywords: Hypertension Kidney Diseases Vitamin D Omega 3 fatty acids
Sponsor: Albert Einstein College of Medicine
Start date: 2016-04-01; Completion date: 2022-03-31
Enrollment: 2232 participants; Allocation: RANDOMIZED; Intervention model: FACTORIAL

Brief summary:
The VITamin D and OmegA-3 TriaL (VITAL; NCT01169259) is an ongoing randomized clinical trial in 25,875 US men and women investigating whether taking dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor (R) fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The VITAL Kidney Function in Hypertension ancillary study will evaluate the effects of vitamin D or omega-3 fatty acids on kidney function among participants with baseline hypertension.

Detailed description:
This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) will test whether vitamin D3, omega-3 fatty acids, or both prevent the development and progression of kidney disease in participants with hypertension. Persons with hypertension are at high risk of kidney disease.

Vitamin D and omega-3 fatty acids are promising interventions for kidney disease prevention and treatment, based on results of animal-experimental models and early human studies. Because these interventions are relatively safe, inexpensive, and widely available, they may offer opportunity to substantially reduce the burden of kidney disease in large populations. This VITAL ancillary study will test whether vitamin D3 and/or omega-3 fatty acids prevent loss of glomerular filtration rate, over 4 years of therapy.

In VITAL, 25,875 participants have been randomly assigned in a 2x2 factorial design to vitamin D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid 465 mg plus docosahexaenoic acid 375 mg daily versus placebo, and followed for a mean of 5 years to assess effects on cardiovascular disease and cancer events. This ancillary study will identify and recruit a sub-cohort of VITAL participants with hypertension at baseline and ascertain effects of study interventions on glomerular filtration rate in this group. Blood samples will be collected at year 4 simultaneously for measurement of estimated glomerular filtration rate (using serum creatinine and cystatin C) and other relevant biomarkers. This VITAL ancillary study is designed to determine whether vitamin D3 and/or omega-3 fatty acids have causal and clinically relevant effects on the development and progression of kidney disease in hypertensives.

Arms: arm 1: Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.

Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]). arm 2: Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.

Dietary Supplement: Omega-3 fatty acid placebo (Fish oil placebo) arm 3: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Dietary Supplement: Vitamin D placebo. One capsule per day Vitamin D3 placebo arm 4: Dietary Supplement: Vitamin D placebo. One capsule per day Vitamin D3 placebo

Dietary Supplement: Omega-3 Fatty acid Placebo (Fish oil placebo). One capsule per day
Interventions: intervention 1: Vitamin D3 intervention 2: Omega-3 Fatty acids intervention 3: Vitamin D3 placebo intervention 4: Fish oil placebo
Intervention descriptions: intervention 1: Vitamin D3 (cholecalciferol), 2000 IU per day intervention 2: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]) intervention 3: Vitamin D3 placebo intervention 4: Fish oil placebo

Protocol documents:
Prot_000.pdf: 
PARTNERS HUMAN RESEARCH COMMITTEE
PROTOCOL SUMMARY
Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
1
Answer all questions accurately and completely in order to provide the PHRC with the relevant 
information to assess the risk-benefit ratio for the study.  Do not leave sections blank.
PRINCIPAL/OVERALL INVESTIGATOR
Michal L. Melamed, MD, MHS, Overall Principal Investigator (Albert Einstein 
College of Medicine)
JoAnn Manson, MD, DrPH, Partners Principal Investigator
PROTOCOL TITLE
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
FUNDING
National Institutes of Health R01 DK102952-01
VERSION DATE
August 28, 2015
SPECIFIC AIMS
Concisely state the objectives of the study and the hypothesis being tested.
To test whether cholecalciferol (vitamin D3, 2000 IU per day) and/or marine omega-3 fatty acids 
(ω-3 FA, eicosapentaenoic acid plus docosahexaenoic acid, 1 gm per day) prevent the 
development and progression of kidney disease in individuals with hypertension, compared with 
placebo.
BACKGROUND AND SIGNIFICANCE
Provide a brief paragraph summarizing prior experience important for understanding the 
proposed study and procedures. 
Chronic kidney disease (CKD) is a common and morbid complication of hypertension.  
Preventing the development and progression of CKD is a critical goal for improving long-term 
health outcomes of the hypertensive population and for reducing the overall burden of kidney 
disease in the United States.  Therefore, there is an urgent need for additional, complementary 
interventions to prevent and treat CKD associated with hypertension.  This need is greatest 
among older adults because hypertension and kidney disease are highly prevalent among older 
adults and kidney disease is among the strongest risk factors for mortality in this group.  Vitamin 
D and omega-3 fatty acids (ω-3 FA) are two of the most promising interventions for CKD 
prevention and treatment.  Because cholecalciferol and ω-3 FA are relatively safe, inexpensive, 
and widely available, they may offer opportunity to substantially reduce the burden of CKD in 
large populations.  Prior to widespread implementation, however, these hypothesized benefits 
should be rigorously tested in well-powered clinical trials.  
RESEARCH DESIGN AND METHODS
Briefly describe study design and anticipated enrollment, i.e., number of subjects to be enrolled 
by researchers study-wide and by Partners researchers.  Provide a brief summary of the 
eligibility criteria (for example, age range, gender, medical condition).  Include any local site 
restrictions, for example, “Enrollment at Partners will be limited to adults although the sponsor’s 
protocol is open to both children and adults.”
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
2
This protocol summary describes an ancillary study to the NIH-funded VITamin D and OmegA-3 
TriaL (VITAL), an NIH-funded randomized, double-blind, placebo-controlled trial.  The overall 
goal of the ancillary study is to determine whether cholecaliferol and/or ω-3 FA supplementation 
prevents the development and progression of kidney disease in participants with baseline 
hypertension and no diabetes mellitus.  
All participants in our ancillary study must be existing participants in the parent VITAL study.  
The parent VITAL study is being conducted among 25,875 healthy participants.  The VITAL 
study population is restricted to older individuals (men ages ≥ 50 years, women ages ≥ 55 
years), because rates of chronic disease (including CVD, cancer, and kidney disease) increase 
substantially with age.  VITAL will exclude persons with clinically apparent CVD or cancer 
(except non-melanoma skin cancer), because it is a trial for the primary prevention of these 
conditions.  Other eligibility criteria are focused largely on safety.  VITAL oversampled for 
participants of black and Hispanic race/ethnicity.  
To initiate our VITAL Hypertensive Kidney ancillary study, we will identify and recruit a sub-
cohort of 4,000 VITAL participants with hypertension at baseline.  Among this group, we will test 
whether the randomly assigned VITAL cholecalciferol and ω-3 FA interventions reduce the loss 
of estimated glomerular filtration rate (GFR) or the prevalence of albuminuria at year 4.  
We will collect blood samples after 4 years of therapy to estimate GFR, comparing this to GFR 
estimated from blood samples at pre-randomization baseline collected by the parent VITAL trial. 
We will also collect urine samples at year 4 post-randomization.
Briefly describe study procedures.  Include any local site restrictions, for example, “Subjects 
enrolled at Partners will not participate in the pharmacokinetic portion of the study.”  Describe 
study endpoints.
For the VITAL Hypertensive Kidney ancillary study described herein, we will collect 
questionnaire data, urine samples, and blood samples.  Questionnaires will address 
hypertension diagnosis, hypertension history, history of kidney disease, and medication use 
related to hypertension and kidney disease. Blood samples will be collected after 4 years of 
therapy at local medical providers or via a phlebotomy service at the participant’s home and 
submitted via mail. Urine samples will be collected and home and submitted via mail after 4 
years of therapy.
There is another VITAL ancillary study which is currently funded to collect bloods on 400 
participants at year 4.  It is important to minimize participant burden and eliminate the possibility 
that a subject would be asked to provide 2 blood samples in the same follow-up period. Thus, 
we would like to clarify that, in the event that a participant in the VITAL Hypertension Kidney 
ancillary study is also selected for the subgroup of N=400 that will be asked to provide a blood 
sample at 4 years for the other ancillary study, the VITAL Hypertensive Kidney ancillary study 
will NOT collect a separate/additional 4 year follow-up sample from that participant. We will only 
send the kidney questionnaire to participants not in the N=400 subgroup.
For studies involving treatment or diagnosis, provide information about standard of care at 
Partners (e.g., BWH, MGH) and indicate how the study procedures differ from standard care.  
Provide information on available alternative treatments, procedures, or methods of diagnosis.
Not applicable.
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
3
Describe how risks to subjects are minimized, for example, by using procedures which are 
consistent with sound research design and which do not unnecessarily expose subjects to risk or 
by using procedures already being performed on the subject for diagnostic or treatment purposes.
The potential risk of disclosure of confidential information is guarded against by maintaining 
completed questionnaires and blood test results in locked files accessible by authorized 
personnel only.
Describe explicitly the methods for ensuring the safety of subjects.  Provide objective criteria for 
removing a subject from the study, for example, objective criteria for worsening disease/lack of 
improvement and/or unacceptable adverse events.  The inclusion of objective drop criteria is 
especially important in studies designed with placebo control groups.
This ancillary study is not administering any treatments.  All treatment monitoring occurs 
through the parent VITAL study.
FORESEEABLE RISKS AND DISCOMFORTS
Provide a brief description of any foreseeable risks and discomforts to subjects.  Include those 
related to drugs/devices/procedures being studied and/or administered/performed solely for 
research purposes.  In addition, include psychosocial risks, and risks related to privacy and 
confidentiality.  When applicable, describe risks to a developing fetus or nursing infant.
The blood draw may cause pain at the place where the needle is inserted, bruising, a 
hematoma (collection of blood underneath the skin), or infection at the place where the needle 
is inserted. Some people feel anxious with blood draws and may faint.  There is also the 
possibility of social/psychological risk that could result from inadvertent disclosure of confidential 
information from the questionnaires or blood tests.
EXPECTED BENEFITS
Describe both the expected benefits to individual subjects participating in the research and the 
importance of the knowledge that may reasonably be expected to result from the study.  Provide 
a brief, realistic summary of potential benefits to subjects, for example, “It is hoped that the 
treatment will result in a partial reduction in tumor size in at least 25% of the enrolled subjects.”  
Indicate how the results of the study will benefit future patients with the disease/condition being 
studied and/or society, e.g., through increased knowledge of human physiology or behavior, 
improved safety, or technological advances.
For the majority of participants, there will be no direct benefits from participating in this study 
other than the awareness of being involved in a large endeavor to answer relevant and timely 
questions regarding the possible benefit of vitamin D and fish oil on hypertensive kidney 
disease.
EQUITABLE SELECTION OF SUBJECTS
The risks and benefits of the research must be fairly distributed among the populations that stand 
to benefit from it.  No group of persons, for example, men, women, pregnant women, children, 
and minorities, should be categorically excluded from the research without a good scientific or 
ethical reason to do so.  Please provide the basis for concluding that the study population is 
representative of the population that stands to potentially benefit from this research.
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
4
The VITAL Hypertensive Kidney study will reflect the hypertensive parent VITAL study 
population.  The parent VITAL study is being conducted among almost 26,000 apparently 
healthy participants.  The VITAL Hypertensive Kidney study population is restricted to older 
individuals (men ages ≥ 60 years, women ages ≥ 65 years), because rates of kidney disease 
increase substantially with age. VITAL oversampled for participants of black and Hispanic 
race/ethnicity, therefore, we expect the VITAL Hypertensive Kidney study will also have an 
adequate representation of participants of black and Hispanic race/ethnicity.
The VITAL Hypertensive Kidney study will enroll approximately 4000 prospective VITAL 
participants who indicate they have a diagnosis of hypertension, and who are willing to 
participate in the VITAL Hypertensive Kidney ancillary study. 
When people who do not speak English are excluded from participation in the research, provide 
the scientific rationale for doing so.  Individuals who do not speak English should not be denied 
participation in research simply because it is inconvenient to translate the consent form in 
different languages and to have an interpreter present.
The VITAL Hypertensive Kidney study will be conducted entirely by mail.  Fluency in the English 
language is required for safe participation.
For guidance, refer to the following Partners policy:
          Obtaining and Documenting Informed Consent of Subjects who do not Speak English
          http://healthcare.partners.org/phsirb/nonengco.htm
RECRUITMENT PROCEDURES
Explain in detail the specific methodology that will be used to recruit subjects.  Specifically 
address how, when, where and by whom subjects will be identified and approached about 
participation.  Include any specific recruitment methods used to enhance recruitment of women 
and minorities.
Persons willing to participating in the parent VITAL trial will return their year 4 questionnaires.  
Those who respond “YES” to the question “Have you EVER been diagnosed as having high 
blood pressure?” on their baseline questionnaires and have a pre-randomization blood sample 
available and who indicated "YES" or "MAYBE" to the question "Are you willing to give a blood 
sample?" (in addition to meeting initial parent VITAL trial eligibility criteria) will be targeted for 
VITAL Hypertensive Kidney ancillary study recruitment. Participants will also have to have 
answered “NO” to “Have you EVER been diagnosed as having diabetes?” After the participants 
return their year 4 questionnaires we will send eligible patients a separate questionnaire 
including:

Letter explaining the rationale for the VITAL Hypertensive Kidney ancillary study, 

Hypertensive Kidney ancillary study informed consent form, 

Hypertensive Kidney ancillary study questionnaire, and

Self-addressed, pre-paid FedEx box for returning study materials.  
The VITAL Hypertensive Kidney ancillary study letter will outline what participation in the VITAL 
Hypertensive Kidney ancillary study would entail and will provide sources for further information 
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
5
on relevant scientific issues.  It will explain that participation in the ancillary study is optional and 
that it will not affect participation in the parent VITAL trial.  
The VITAL Hypertensive Kidney ancillary study questionnaire will include items which clarify the 
self-reported diagnosis of hypertension and further define hypertension and kidney disease 
history, including previous dialysis treatments.  All persons will have the option to decline VITAL 
Hypertensive Kidney ancillary study participation by checking a single box on their initial contact 
letter and returning this by mail to the VITAL coordinating center, or by calling the toll-free VITAL 
telephone number.
All potential participants who return a valid VITAL Hypertensive Kidney ancillary study consent 
form and agree to blood draws will be enrolled in the VITAL Hypertensive Kidney ancillary 
study.  In the consent form, participants will decide whether they want to get bloods drawn by 
their local physician or clinic or whether they want a phlebotomy service to come to their home 
to draw the bloods. Blood and urine collection kits will then be mailed to the participants.  
Follow-up telephone calls will be used to remind potential participants to complete blood and 
urine collections, if needed.  The first 4,000 VITAL participants who return the informed consent 
form, the Hypertensive Kidney questionnaire and the bloods and urine will be enrolled in the 
VITAL Hypertensive Kidney ancillary study.  
Provide details of remuneration, when applicable.  Even when subjects may derive medical 
benefit from participation, it is often the case that extra hospital visits, meals at the hospital, 
parking fees or other inconveniences will result in additional out-of-pocket expenses related to 
study participation.  Investigators may wish to consider providing reimbursement for such 
expenses when funding is available
Participants will receive $50 for participation in this study.
For guidance, refer to the following Partners policies:
          Recruitment of Research Subjects 
          http://healthcare.partners.org/phsirb/recruit.htm
          Guidelines for Advertisements for Recruiting Subjects
          http://healthcare.partners.org/phsirb/advert.htm
          Remuneration for Research Subjects
          http://healthcare.partners.org/phsirb/remun.htm
CONSENT PROCEDURES
Explain in detail how, when, where, and by whom consent is obtained, and the timing of consent 
(i.e., how long subjects will be given to consider participation).  For most studies involving more 
than minimal risk and all studies involving investigational drugs/devices, a licensed physician 
investigator must obtain informed consent.  When subjects are to be enrolled from among the 
investigators’ own patients, describe how the potential for coercion will be avoided.
A VITAL Hypertensive Kidney consent form will be mailed to each potential participant as part of 
their initial VITAL Hypertensive Kidney ancillary study packet.  
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
6
All persons will have the option to decline VITAL Hypertensive Kidney ancillary study 
participation by checking a single box on their initial contact letter and returning this by mail to 
the VITAL coordinating center, or by calling the toll-free VITAL telephone number.  
The initial contact letter and consent form will encourage participants to ask questions or 
address concerns by calling the toll-free VITAL telephone number to speak with study staff in 
person.  Willing potential participants will return the final signature page of their consent forms to 
the VITAL coordinating center by mail.  The consent form has been formatted so that all 
information about the study appears on pages 1 through 8 of the form, and the final page, page 
9 contains the “Informed consent and authorization” section, which the participant is instructed 
to read and, if in agreement, to sign. This signature page (page 9 of the consent form) will be 
formatted in Teleform software which allows for the data on the form [signed OR not signed] and 
the image of the form to be captured via an optical scan process. Study staff will contact 
potential participants by telephone to clarify ambiguous or invalid consent forms.
NOTE: When subjects are unable to give consent due to age (minors) or impaired decision-
making capacity, complete the forms for Research Involving Children as Subjects of Research 
and/or Research Involving Individuals with Impaired Decision-making Capacity, available on 
the New Submissions page on the PHRC website: 
http://healthcare.partners.org/phsirb/newapp.htm#Newapp
For guidance, refer to the following Partners policy:
          Informed Consent of Research Subjects
          http://healthcare.partners.org/phsirb/infcons.htm
DATA AND SAFETY MONITORING
Describe the plan for monitoring the data to ensure the safety of subjects.  The plan should 
include a brief description of (1) the safety and/or efficacy data that will be reviewed; (2) the 
planned frequency of review; and (3) who will be responsible for this review and for determining 
whether the research should be altered or stopped.  Include a brief description of any stopping 
rules for the study, when appropriate.  Depending upon the risk, size and complexity of the 
study, the investigator, an expert group, an independent Data and Safety Monitoring Board 
(DSMB) or others might be assigned primary responsibility for this monitoring activity.       
NOTE: Regardless of data and safety monitoring plans by the sponsor or others, the principal 
investigator is ultimately responsible for protecting the rights, safety, and welfare of subjects 
under his/her care.
An independent Data and Safety Monitoring Board (DSMB) has been assembled for the parent 
VITAL trial, consisting of experts in clinical trials, epidemiology, biostatistics, relevant clinical 
areas of cancer and CVD, and NIH representatives. If necessary, the DSMB will review adverse 
events related to VITAL ancillary studies, including VITAL Hypertensive Kidney.
Describe the plan to be followed by the Principal Investigator/study staff for review of adverse 
events experienced by subjects under his/her care, and when applicable, for review of sponsor 
safety reports and DSMB reports.  Describe the plan for reporting adverse events to the sponsor 
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
7
and the Partners’ IRB and, when applicable, for submitting sponsor safety reports and DSMB 
reports to the Partners’ IRBs.  When the investigator is also the sponsor of the IND/IDE, include 
the plan for reporting of adverse events to the FDA and, when applicable, to investigators at 
other sites.  
NOTE: In addition to the adverse event reporting requirements of the sponsor, the principal 
investigator must follow the Partners Human Research Committee guidelines for Adverse Event 
Reporting
All potential adverse events arising from parent VITAL study interventions will be reviewed by 
investigators leading the parent VITAL study.
MONITORING AND QUALITY ASSURANCE
Describe the plan to be followed by the principal investigator/study staff to monitor and assure 
the validity and integrity of the data and adherence to the IRB-approved protocol.  Specify who 
will be responsible for monitoring, and the planned frequency of monitoring.  For example, 
specify who will review the accuracy and completeness of case report form entries, source 
documents, and informed consent.  
NOTE: Regardless of monitoring plans by the sponsor or others, the principal investigator is 
ultimately responsible for ensuring that the study is conducted at his/her investigative site in 
accordance with the IRB-approved protocol, and applicable regulations and requirements of the 
IRB.
Because participants will be followed solely by mail, the VITAL computing system is a critical 
feature of effective recruiting and follow-up. This system, which was developed and fine-tuned in 
previous trials led by VITAL investigators, tracks each participant’s stage in the study and level 
of participation.  Computer systems allow access by study personnel to identify information 
while maintaining strict security.  Questionnaire data will be optically scanned into the computer. 
The relevant software—TELEform and Alchemy (Cardiff Software)—has been successfully used 
for several years in the Women’s Health Study and Physicians’ Health Study.  All data undergo 
additional within-form and across-time checks to verify accuracy; and are backed up nightly.
For guidance, refer to the following Partners policies:
          Data and Safety Monitoring Plans and Quality Assurance
          http://healthcare.partners.org/phsirb/datasafe.htm
          Adverse Event Reporting Guidelines
          http://healthcare.partners.org/phsirb/adverse_events.htm
PRIVACY AND CONFIDENTIALITY
Describe methods used to protect the privacy of subjects and maintain confidentiality of data 
collected.  This typically includes such practices as substituting codes for names and/or medical 
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
8
record numbers; removing face sheets or other identifiers from completed 
surveys/questionnaires; proper disposal of printed computer data; limited access to study data; 
use of password-protected computer databases; training for research staff on the importance of 
confidentiality of data, and storing research records in a secure location.  
NOTE: Additional measures, such as obtaining a Certificate of Confidentiality, should be 
considered and are strongly encouraged when the research involves the collection of sensitive 
data, such as sexual, criminal or illegal behaviors.
The potential risk of disclosure of confidential information is guarded against by maintaining 
completed questionnaires and blood test results in locked files accessible by authorized 
personnel only. In these files, participants are identified only by study ID. Subject identifiers are 
stored in separate computer files with password protection, and results will be presented only in 
the aggregate. In addition, employees involved with the proposed study will be asked to sign a 
form agreeing not to disclose any information to which they might have access, regardless of 
their personal perception about its confidentiality. Each employee of the study with human 
subject contact participates in an institutional (Brigham and Women’s Hospital) human subjects 
educational program, which consists of reviewing regulatory and informational documents 
pertaining to human subjects research; passing a test on ethical principles and regulations 
governing human subjects research; and signing a statement of commitment to the protection of 
human subjects.  Finally, all such employees are required to participate in HIPAA training.
SENDING SPECIMENS/DATA TO RESEARCH COLLABORATORS OUTSIDE 
PARTNERS
Specimens or data collected by Partners investigators will be sent to research collaborators 
outside Partners, indicate to whom specimens/data will be sent, what information will be sent, 
and whether the specimens/data will contain identifiers that could be used by the outside 
collaborators to link the specimens/data to individual subjects.
Data will be sent from Partners investigators to the overall Principal Investigator of this ancillary 
study:  Michal L. Melamed, MD, MHS, at the Albert Einstein College of Medicine (Bronx, NY).  
Data will include demographics, comorbidities, medication use, and adherence to study 
medications (all assessed by questionnaire); treatment assignments; and laboratory data 
generated by the parent VITAL study.  Specimens will be sent from Partners investigators to a 
co-Investigator: Ian de Boer, MD, MS, at the University of Washington (Seattle, WA). 
Specimens will include urine and blood. The University of Washington will perform laboratory 
studies for this ancillary study including: serum creatinine, cystatin C and FGF-23 and urine 
albumin and creatinine levels. All biospecimens and data will be completely free of identifiers 
that could be used to link the specimens and data to individual subjects.
Specifically address whether specimens/data will be stored at collaborating sites outside 
Partners for future use not described in the protocol.  Include whether subjects can withdraw 
their specimens/data, and how they would do so.  When appropriate, submit documentation of 
IRB approval from the recipient institution.
Specimens and data stored at the University of Washington and the Albert Einstein College of 
Medicine will be used only for the procedures described in the study protocol.  Participants may 
withdraw their specimens and data at any time by request in writing to the VITAL coordinating 
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018


Partners Human Subjects Research Application Form
Filename: Protocol Summary
Version Date:  June 1, 2005
 
9
center.  The ancillary study proposed herein will be submitted to the Albert Einstein College of 
Medicine IRB concurrent with submission to the Partner's IRB.
RECEIVING SPECIMENS/DATA FROM RESEARCH COLLABORATORS OUTSIDE 
PARTNERS
When specimens or data collected by research collaborators outside Partners will be sent to 
Partners investigators, indicate from where the specimens/data will be obtained and whether the 
specimens/data will contain identifiers that could be used by Partners investigators to link the 
specimens/data to individual subjects.  When appropriate, submit documentation of IRB 
approval and a copy of the IRB-approved consent form from the institution where the 
specimens/data were collected.
Not applicable.
IRB NUMBER: 2014-3778
IRB APPROVAL DATE: 08/10/2018